Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EM05
|
| gptkbp:brand |
gptkb:Ukoniq
|
| gptkbp:CASNumber |
1353552-87-6
|
| gptkbp:chemicalFormula |
C32H32N8O2S
|
| gptkbp:developedBy |
gptkb:TG_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
umbralisib
|
| gptkbp:legalStatus |
withdrawn
|
| gptkbp:mechanismOfAction |
PI3K delta inhibitor
CK1 epsilon inhibitor |
| gptkbp:retired |
safety concerns
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
infections elevated liver enzymes neutropenia |
| gptkbp:usedFor |
treatment of follicular lymphoma
treatment of marginal zone lymphoma |
| gptkbp:withdrawn |
2022
true |
| gptkbp:bfsParent |
gptkb:O00329_(PIK3CD)
gptkb:PIK3CD |
| gptkbp:bfsLayer |
5
|